Let’s Talk Turkey About Dou­ble Chins

Phar­ma­ceu­ti­cals ▶ Al­ler­gan, which gave us Bo­tox, rolls out a drug for droopy jowls ▶ “Now we’re al­most a one-stop shop. We own the face”

Bloomberg Businessweek (North America) - - Companies / Industries -

Two decades ago, Al­ler­gan turned the der­ma­tol­ogy world on its head with its wrin­kle-re­duc­ing Bo­tox. Now the com­pany hopes to do the same with Ky­bella, the first in­jectable treat­ment for what doc­tors call “sub­men­tal fat”— what the rest of us think of as the goop in­side dou­ble chins. “It’s a dis­rup­tive tech­nol­ogy,” says Philippe Schai­son, pres­i­dent of Al­ler­gan’s U.S. med­i­cal busi­ness. “It’s work­ing great, and there’s noth­ing like it.”

Soon af­ter the Food and Drug Ad­min­is­tra­tion ap­proved the chin treat­ment in April 2015, Al­ler­gan bought its de­vel­oper, Kythera Bio­phar­ma­ceu­ti­cals, for $2.1 bil­lion. Since then it’s trained 1,600 U.S. and Cana­dian doc­tors to ad­min­is­ter the drug. In Septem­ber it will launch a mar­ket­ing blitz in­clud­ing TV spots to woo dou­ble-chin-con­scious con­sumers.

The ac­tive in­gre­di­ent in Ky­bella, de­oxy­cholic acid, is a form of bile that de­stroys fat cells in the di­ges­tive tract. It does the same in the chin. The

4m 2m

Newspapers in English

Newspapers from Canada

© PressReader. All rights reserved.